A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

• Status: Withdrawn
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oryn Therapeutics, LLC

Criteria

Inclusion Criteria:

• Positive RT-PCR assay for SARS CoV-2 in a respiratory tract sample

• Hospitalized for COVID-19

• Radiographic diagnosis of pneumonia

• Respiratory insufficiency

• Receiving pharmacologic thromboprophylaxis

Exclusion Criteria:

• Premorbid abnormal pulmonary function or disease

• Concurrent or prior intubation or ventilated support for COVID-19

• Receiving systemic corticosteroids or other immunomodulators or immunosuppressant drugs

• Previous hospitalization for COVID-19